Mometasone Furoate Ointment Potency Classification
Mometasone furoate 0.1% ointment is classified as a medium-potency (Class 4-5) topical corticosteroid, not upper-middle potency. 1, 2
Official Classification
The FDA drug label explicitly states that "Mometasone furoate cream USP 0.1% is a medium potency corticosteroid" 2. This classification applies to both the cream and ointment formulations at 0.1% concentration.
Guideline-Based Potency Rankings
According to the 2021 Joint AAD-NPF Guidelines for psoriasis management, topical corticosteroids are classified into 7 categories based on vasoconstriction activity 1. Within this system:
- Mometasone furoate 0.1% in cream/ointment/lotion formulations is listed in the middle-potency range (Class 4-5) 1
- This places it alongside other medium-potency agents like hydrocortisone valerate 0.2%, fluocinolone acetonide 0.025%, and triamcinolone acetonide 0.1% 1
Clinical Context
The term "medium-high potency" has been used in some older research literature 3, but this is not the standard classification used in current guidelines or FDA labeling. The official designation remains "medium potency."
Practical Implications:
- Medium-potency steroids like mometasone can be used for longer treatment courses compared to high or very-high potency agents due to a more favorable adverse event profile 4
- For initial therapy in adults with psoriasis or atopic dermatitis, corticosteroids in classes 2-5 (moderate to high potency) are generally recommended 1
- Mometasone is appropriate for maintenance therapy when used intermittently (e.g., twice weekly) to reduce disease flares 4
Important Caveats
The vehicle (ointment vs. cream) can affect penetration and clinical potency, with ointments generally providing better penetration than creams 2. However, this does not change the formal potency classification of mometasone furoate 0.1%, which remains medium potency regardless of vehicle 1, 2.